Clinical Trial Update: A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease (AD) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating p38 MAP kinase inhibitor VX-745 on amyloid plaque load in Alzheimer's disease and mild cognitive impairment has completed with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Drugs mentioned

• VX-745 (VX-745)

Snippet

Sponsor: EIP Pharma Inc | Conditions: Alzheimer's Disease, Mild Cognitive Impairment | Phase 2 | Status: COMPLETED | Results posted: 2019-06-14